-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenDaiichi Sankyo2022-08-18 15:09:25Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with HER2 Positive Metastatic
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseDaiichi Sankyo2022-06-23 16:27:20Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic
-
DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell CarcinomaDaiichi Sankyo2022-06-07 17:50:00DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma
-
ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative DiseaseDaiichi Sankyo2022-06-07 17:41:49ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low
-
Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung CancerDaiichi Sankyo2022-06-03 15:23:19Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic
-
Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data presentations at EAS 2022Daiichi Sankyo2022-05-24 17:09:00Daiichi Sankyo Europe highlights need to address the perception and classification of CVD risk with data
-
People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to Refocus on Cardiovascular CareDaiichi Sankyo2022-05-24 17:15:36People Who Have Had COVID-19 More Likely to Develop Cardiovascular Disease: New Report Highlights the Need to
-
ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2 Low Metastatic Breast CancerDaiichi Sankyo2022-02-21 12:51:35ENHERTU® Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in
-
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenDaiichi Sankyo2022-01-17 12:35:39ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated
-
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based RegimenDaiichi Sankyo2021-12-28 09:57:56Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive
